More recently, new GLP-1RAs, such as semaglutide or supaglutide, have been developed showing similar or even greater benefits in terms of weight loss, induction of EE and browning of WAT in mice models of obesity, thus further corroborating previous evidence regarding the thermogenic role of GLP-1R activation [164, 165]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.